Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.69 |
| ▸ | CTSK | P43235 | 10/20 | 0.69 |
| ▸ | CTSB | P07858 | 4/20 | 0.69 |
| ▸ | CTSL | P07711 | 2/20 | 0.69 |
| ▸ | AKT1 | P31749 | 1/20 | 0.67 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PTPRA | P18433 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440946 | 0.90 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL21010315 | 0.90 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5408851 | 0.89 | CTSS (0.67) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL16288190 | 0.88 | CTSS (0.72) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5873387 | 0.88 | CTSS (0.72) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5873364 | 0.88 | CTSS (0.72) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2442760 | 0.88 | CTSS (0.76) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2446582 | 0.88 | CTSS (0.76) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10040933 | 0.88 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2444606 | 0.87 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | CTSS 3490/4885CTSK 4240/4885CTSB 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.